The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Chronic hepatitis B virus infection in Asian countries
Abstract
Of the estimated 50 million new cases of hepatitis B virus (HBV) infection diagnosed annually, 5–10% of adults and up to 90% of infants will become chronically infected, 75% of these in Asia where hepatitis B is the leading cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC). In Indonesia, 4.6% of the population was positive for HBsAg in 1994 and of these, 21% were positive for HBeAg and 73% for anti‐HBe; 44% and 45% of Indonesian patients with cirrhosis and HCC, respectively, were HBsAg positive. In the Philippines, there appear to be two types of age‐specific HBsAg prevalence, suggesting different modes of transmission. In Thailand, 8–10% of males and 6–8% of females are HBsAg positive, with HBsAg also found in 30% of patients with cirrhosis and 50–75% of those with HCC. In Taiwan, 75–80% of patients with chronic liver disease are HBsAg positive, and HBsAg is found in 34% and 72% of patients with cirrhosis and HCC, respectively. In China, 73% of patients with chronic hepatitis and 78% and 71% of those with cirrhosis and HCC, respectively, are HBsAg positive. In Singapore, the prevalence of HBsAg has dropped since the introduction of HBV vaccination and the HBsAg seroprevalence of unvaccinated individuals over 5 years of age is 4.5%. In Malaysia, 5.24% of healthy volunteers, with a mean age of 34 years, were positive for HBsAg in 1997. In the highly endemic countries in Asia, the majority of infections are contracted postnatally or perinatally. Three phases of chronic HBV infection are recognized: phase 1 patients are HBeAg positive with high levels of virus in the serum and minimal hepatic inflammation; phase 2 patients have intermittent or continuous hepatitis of varying degrees of severity; phase 3 is the inactive phase during which viral concentrations are low and there is minimal inflammatory activity in the liver. In general, patients who clear HBeAg have a better prognosis than patients who remain HBeAg‐positive for prolonged periods of time. The outcome after anti‐HBe seroconversion depends on the degree of pre‐existing liver damage and any subsequent HBV reactivation. Without pre‐existing cirrhosis, there may be only slight fibrosis or mild chronic hepatitis, but with pre‐existing cirrhosis, further complications may ensue. HBsAg‐negative chronic hepatitis B is a phase of chronic HBV infection during which a mutation arises resulting in the inability of the virus to produce HBeAg. Such patients tend to have more severe liver disease and run a more rapidly progressive course. The annual probability of developing cirrhosis varies from 0.1 to 1.0% depending on the duration of HBV replication, the severity of disease and the presence of concomitant infections or drugs. The annual incidence of hepatic decompensation in HBV‐related cirrhosis varies from 2 to 10% and in these patients the 5‐year survival rate drops dramatically to 14–35%. The annual risk of developing HCC in patients with cirrhosis varies between 1 and 6%; the overall reported annual detection rate of HCC in surveillance studies, which included individuals with chronic hepatitis B and cirrhosis, is 0.8–4.1%. Chronic hepatitis B is not a static disease and the natural history of the disease is affected by both viral and host factors. The prognosis is poor with decompensated cirrhosis and effective treatment options are limited. Prevention of HBV infection thorough vaccination is still, therefore, the best strategy for decreasing the incidence of hepatitis B‐associated cirrhosis and HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
Liaw, Y.-F., Tai, D.-I., Chu, C.-M., & Chen, T.-J. (1988) · Hepatology · doi:10.1002/hep.1840080310 · Cited by 612
Survival and prognostic indicators in compensated and decompensated cirrhosis
D'amico, G., Morabito, A., Pagliaro, L., Marubini, E., & The Liver Study Group of ?V. Cervello? Hospital (1986) · Digestive Diseases and Sciences · doi:10.1007/bf01320309 · Cited by 575
DI BISCEGLIE, A. M., RUSTGI, V. K., HOOFNAGLE, J. H., DUSHEIKO, G. M., & LOTZE, M. T. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-390 · Cited by 454
Screening for hepatocellular carcinoma
Collier, J., & Sherman, M. (1998) · Hepatology · doi:10.1002/hep.510270140 · Cited by 425
Chu, C.-M., Karayiannis, P., Fowler, M. J. F., Monjardino, J., Liaw, Y.-F., & Thomas, H. C. (1985) · Hepatology · doi:10.1002/hep.1840050315 · Cited by 419
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
De Jongh, F. E., Janssen, H. L. A., De Man, R. A., Hop, W. C. J., Schalm, S. W., & Van Blankenstein, M. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91188-a · Cited by 418
Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis
Oka, H., Kurioka, N., Kim, K., Kanno, T., Kuroki, T., Mizoguchi, Y., & Kobayashi, K. (1990) · Hepatology · doi:10.1002/hep.1840120411 · Cited by 392
Fattovich, G., Giustina, G., Schalm, S. W., Hadziyannis, S., Sanchez-Tapias, J., Almasio, P., Christensen, E., Krogsgaard, K., Degos, F., De Moura, M. C., et al. (1995) · Hepatology · doi:10.1002/hep.1840210114 · Cited by 369
Liaw, Y.-F., Chu, C.-M., Su, I.-J., Huang, M.-J., Lin, D.-Y., & Chang-Chien, C.-S. (1983) · Gastroenterology · doi:10.1016/s0016-5085(83)80114-0 · Cited by 341
Lok, A. S. F., Lai, C.-L., Wu, P.-C., Leung, E. K. Y., & Lam, T.-S. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90613-5 · Cited by 326
Cited by
What is the best multi-stage architecture for object recognition?
Jarrett, K., Kavukcuoglu, K., Ranzato, M. A., & LeCun, Y. (2009) · 2009 IEEE 12th International Conference on Computer Vision · doi:10.1109/iccv.2009.5459469 · Cited by 2,153
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Global burden of aflatoxin-induced hepatocellular carcinoma: A risk assessment
Liu, Y., & Wu, F. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901388 · Cited by 1,224
Improved automatic keyword extraction given more linguistic knowledge
Hulth, A. (2003) · Proceedings of the 2003 conference on Empirical methods in natural language processing - · doi:10.3115/1119355.1119383 · Cited by 951
Histological outcome during long-term lamivudine therapy
Dienstag, J. L., Goldin, R. D., Heathcote, E. J., Hann, H. W. L., Woessner, M., Stephenson, S. L., Gardner, S., Gray, D. F., & Schiff, E. R. (2003) · Gastroenterology · doi:10.1053/gast.2003.50013 · Cited by 726
Metadata
- Authors
- Merican, I., Guan, R., Amarapuka, D., Alexander, M., Chutaputti, A., Chien, R., Hasnian, S., Leung, N., Lesmana, L., Phiet, P., Sjalfoellah Noer, H., Sollano, J., Sun, H., & Xu, D.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2000-12
- Volume
- 15
- Issue
- 12
- Pages
- 1356-1361
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W1988570524
- Cited by
- 505
- References
- 17
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic hepatitis B virus infection in Asian countries. https://app.cochat.ai/papers/10.1046/j.1440-1746.2000.0150121356.x
- The paper
- Merican, I., Guan, R., Amarapuka, D., Alexander, M., Chutaputti, A., Chien, R., Hasnian, S., Leung, N., Lesmana, L., Phiet, P., Sjalfoellah Noer, H., Sollano, J., Sun, H., & Xu, D. (2000). Chronic hepatitis B virus infection in Asian countries. Journal of Gastroenterology and Hepatology. https://doi.org/10.1046/j.1440-1746.2000.0150121356.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.